Low red blood cell levels of deglycating enzymes in colorectal cancer patients

Table 1 Clinical characteristics of subjects enrolled in the study (mean ± SD)

	Control subjects	Adenoma patients	Cancer patients
n	11	33	16
Age (yr)	45 ± 5.8	67.6 ± 11.7	68.1 ± 6.4
Female/male	5/6	15/18	10/6
Glycemia (mmol/L)	4.87 ± 0.2	5.82 ± 1.2	7.06 ± 2.4
BMI (kg/m2)	25.6 ± 7.7	27.8 ± 6.3	27.1 ± 3.1

BMI: Body mass index.

Table 2 Red blood cell levels of Glyoxalase I and fructosamine-3-kinase activity in controls, adenoma and tumor-bearing patients (mean ± SD)

	Glyoxalase I	FN3K
Controls (n = 11)	0.173 ± 0.25	29.05 ± 14.6
Adenomas (n = 33)	0.128 ± 0.19a	38.6 ± 31.7b
Tumors (n = 16)	0.022 ± 0.01a	19.55 ± 6.4b

^a,bP < 0.05, Tukey’s test. The glyoxalase enzymatic activity is expressed as mmol/min per milliliter of red blood cells and the enzymatic activity of FN3K is expressed as pmol/min per milliliter of red blood cells. FN3K: Fructosamine-3-kinase.